DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme January 29, 2020 • 8:00 AM EST
DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019 December 3, 2019 • 8:30 AM EST
DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM November 25, 2019 • 9:51 AM EST
DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates November 14, 2019 • 8:00 AM EST
DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083 November 5, 2019 • 8:30 AM EST
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting October 29, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference October 24, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time October 10, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019 September 11, 2019 • 8:00 AM EDT
DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates September 10, 2019 • 8:00 AM EDT